Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 2
Ce profil est validé par 2 label.

Company

LS CancerDiag

LS CancerDiag_logo
45
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

LS CancerDiag has developed DiagMMR®, a unique predictive diagnostic test to detect Lynch syndrome (LS). We provide easily interpretable and highly accurate results even before cancers develop, enabling preventive and personalized care.

Helsinki, Uusimaa, Finland

Send a message

Anglais

LS CancerDiag

Anglais

LS CancerDiag is committed to reducing cancer mortality rates with a diagnostic method that detects an inherited cancer-causing condition prior to cancer.

DiagMMR® is designed to be a predictive diagnostic tool that enables preventive follow-up and counselling for affected mutation carriers who are at high risk for developing Lynch syndrome related cancers. While current LS diagnosis relies on tumor studies, the quantitative DiagMMR® method allows carrier diagnosis based on a...

See more

LS CancerDiag is committed to reducing cancer mortality rates with a diagnostic method that detects an inherited cancer-causing condition prior to cancer.

DiagMMR® is designed to be a predictive diagnostic tool that enables preventive follow-up and counselling for affected mutation carriers who are at high risk for developing Lynch syndrome related cancers. While current LS diagnosis relies on tumor studies, the quantitative DiagMMR® method allows carrier diagnosis based on a non-invasive tissue sample before the person has developed a cancer, without the knowledge and details of an inherited mutation.

  • 2

    Followers

  • 1

    Like

Our latest news

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not receive funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1483 Entities
InvestHorizon - Accelerated
The InvestHorizon Accelerated label is for selected deep tech companies from the accelerator programme to facilitate series A funding.  This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential. InvestHorizon is a programme financed by the European Commission in association with Eureka to foster investment readiness.
456 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
2675 Members
Access2EIC
Access2EIC is a 7-year coordination and support action which builds upon the foundations laid by previous EIC support networks and in line with the new Horizon Europe Framework Programme. The Access2EIC Community aims to support the best European companies in "transition" stage. https://access2eic.eu/
2144 Members

Our history

Start in Aug 2013

  • Aug 2013

    LS CancerDiag is founded as a Spin-off from the University of Helsinki.

  • 2014-2018

    Patents filed and granted in all major markets (incl. EU, USA, China, Russia, Japan)

  • 2016

    LS CancerDiag joins Startup Health.

  • 2018

    Optimization and validation is completed.

  • 2019

    CE-mark obtained as IVD MD. Distribution agreements signed in Finland.

to be continued ...